U.S. Markets close in 17 mins
S&P 500
3,345.05-4.11(-0.12%)Nasdaq
10,989.91-118.16(-1.06%)Russell 2000
1,560.96+16.33(+1.06%)
Nektar Therapeutics (NKTR)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
21.83+0.32 (+1.49%)
As of 3:43PM EDT. Market open.
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 21.51 |
| Open | 22.50 |
| Bid | 21.81 x 3100 |
| Ask | 21.86 x 800 |
| Day's Range | 21.74 - 22.98 |
| 52 Week Range | 13.63 - 28.60 |
| Volume | 864,556 |
| Avg. Volume | 1,057,706 |
| Market Cap | 3.886B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.43 |
| Earnings Date | Nov 04, 2020 - Nov 09, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.14 |
- Zacks
Nektar's (NKTR) Q2 Earnings Beat, Bempeg Makes Progress
Nektar (NKTR) reports encouraging second-quarter 2020 results. The company continues to progress with its pipeline candidates.
- Zacks
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of 34.78% and 113.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Nektar Therapeutics Reports Second Quarter 2020 Financial Results
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2020.
© 2020 Verizon Media. All rights reserved.
